STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-196)	EFPEGLENATIDE
PRONUNCIATION	ef” peg len’ a tide
THERAPEUTIC CLAIM	Treatment of diabetes

CHEMICAL NAMES

1. Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, 26-ether with *N*-[2-(1*H*-imidazol-5-yl)acetyl]glycyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tryptophyl-L-leucyl-N^6-(3-hydroxypropyl)-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide, 1'-ether with immunoglobulin G4 [1-[1-(3-hydroxypropyl)proline]] (human fragment), (3'→3'')-disulfide with immunoglobulin G4 (human fragment) (Source: CAS)

2. Exenatide derivative and human IgG4 Fc dimer linked together with polyethylene glycol derivative: $N^{6.27}$,$N^{1.9'}$-[ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyethylene)] [1-(imidazol-4-ylacetic acid)]exendin-4 *Heloderma suspectum* (Gila monster), human immunoglobulin G4 Fc fragment-(9'-229')-peptide dimer (11'-11'')-disulfide (Source: proposed WHO INN list #111)

STRUCTURAL FORMULA

Modified exendin-4

HGEGTFTSDL	SKQMEEEAVR	LFIEWLKNGG	PSSGAPPPS	39

hIGHG4 Fc monomer

PS	CPAPEFLGGP	SVFLFPPKPK	DTLMISRTPE	VTCVVVDVSQ	50'
EDPEVQFNWY	VDGVEVHNAK	TKPREEQFNS	TYRVVSVLTV	LHQDWLNGKE	100'
YKCKVSNKGL	PSSIEKTISK	AKGQPREPQV	YTLPPSQEEM	TKNQVSLTCL	150'
VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL	DSDGSFFLYS	RLTVDKSRWQ	200'
EGNVFSCSVM	HEALHNHYTQ	KSLSLSLGK			229'

hIGHG4 Fc monomer

PS	CPAPEFLGGP	SVFLFPPKPK	DTLMISRTPE	VTCVVVDVSQ	50''
EDPEVQFNWY	VDGVEVHNAK	TKPREEQFNS	TYRVVSVLTV	LHQDWLNGKE	100''
YKCKVSNKGL	PSSIEKTISK	AKGQPREPQV	YTLPPSQEEM	TKNQVSLTCL	150''
VKGFYPSDIA	VEWESNGQPE	NNYKTTPPVL	DSDGSFFLYS	RLTVDKSRWQ	200''
EGNVFSCSVM	HEALHNHYTQ	KSLSLSLGK			229''

Disulfide bridges location

11'-11'' 43'-103' 43''-103' 149'-207' 149''-207''

Modified residues

H 1 (imidazol-4-yl)acetic acid



S 39 serinamide



P - K 9' - 27



MOLECULAR FORMULA	$C_{2415}H_{3715}N_{663}O_{743}S_{17}[C_2H_4O]_n$
MOLECULAR WEIGHT	57.0 kDa (n = 66)
TRADEMARK	None as yet
SPONSOR	Sanofi-Aventis Deutschland GmbH
CODE DESIGNATIONS	HM11260C, SAR439977
CAS REGISTRY NUMBER	1296200-77-5
UNII	3M1V5Z2270
WHO NUMBER	9580

gbk